Multiple sclerosis: biomarkers

A project funded by the European Commission
Microbiota-based biomarkers


Extensive research by our team aimed at identifying new intestinal biomarkers to be used to predict patient response to disease-modifying therapy gave rise to ScleroTest, a project funded by the European Commission.

Multiple sclerosis (MS) is a chronic autoimmune disease that causes inflammatory demyelination of neural nerves, resulting in brain damage and neurological disability, and is one of the most common neurodegenerative disorders. Common symptoms of MS include blurred vision, extreme fatigue, pain, numbness in legs and hands, speech problems and possible loss of movement. After traffic accidents, it is the biggest cause of disability in young people and has become a serious public health problem. The World Health Organisation (WHO) estimates that there are 2.5 million people living with the condition worldwide, and its prevalence is expected to increase in the coming years.


Brain damage occurs from the very onset of the disease. There is a short period of time in which neurological deterioration can be halted, which makes early treatment of utmost importance. Although research and resources have increased life expectancy and quality of life for patients, there is currently no cure for the disease.


ScleroTest is a patented technology (European Patent Application No. 19382093.3) designed as a non-invasive rapid diagnostic test based on the identification of microorganisms that can only be found in the gut microbiota of MS patients. These microorganisms determine whether or not the subject has the disease. Moreover, a certain number and proportion of these microorganisms indicate a poor response to treatment and a poorer prognosis for the patient.


This development is the subject of a European patent application, as well as a PCT extension in several territories which have been selected on the basis of disease prevalence and market opportunities.

A patent licence is now available for this biomarker created to aid in the early diagnosis of MS.



    You can also write to us at or call 865 78 01 70.

    All personal data that you submit us via this form will be processed by Data Controller BIOITHAS, S.L. and saved into CONTACTS processing activitie, with the purpose of answering your inquiry, via email or phone, and for a later follow up.

    Processing shall be lawful because you give us your consent for these specific purposes. Your personal data will not be disclosed to third parties unless forced by law. You have right to access to, rectify, or delete your personal data, and other rights as explained in our Privacy Policy:

    Our accreditations

    Innovative SME Seal

    Innovative Technology-Based Enterprise (EIBT) Seal

    BIOITHAS S.L. has been a beneficiary of the European Regional Development Fund.

    A way to make Europe.